NKTR
Nektar Therapeutics NASDAQ$86.89
Pre-mkt
$86.50
-0.45%
Mkt Cap $1.8B
52w Low $7.99
78.1% of range
52w High $109.00
50d MA $76.83
200d MA $53.77
P/E (TTM)
-8.9x
EV/EBITDA
-6.5x
P/B
16.2x
Debt/Equity
1.7x
ROE
-182.7%
P/FCF
-3.4x
RSI (14)
—
ATR (14)
—
Beta
1.18
50d MA
$76.83
200d MA
$53.77
Avg Volume
1.3M
About
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, s…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -2.76 | -1.78 | +35.5% | 70.36 | +3.2% | +4.1% | +2.6% | +6.7% | +4.0% | +6.4% | — |
| Nov 6, 2025 | AMC | -2.85 | -1.85 | +35.1% | 55.12 | +1.6% | +1.5% | +5.2% | +7.5% | +4.6% | -2.1% | — |
| Aug 7, 2025 | AMC | -3.13 | -2.95 | +5.8% | 21.75 | +3.9% | +6.0% | +3.3% | +8.5% | +18.3% | +22.7% | — |
| May 8, 2025 | AMC | -2.70 | -3.30 | -22.2% | 9.28 | -3.3% | -4.8% | +4.0% | +3.3% | +4.1% | -1.1% | — |
| Mar 12, 2025 | AMC | -1.95 | -2.25 | -15.4% | 12.30 | +6.9% | -0.6% | +9.3% | +10.9% | +7.3% | +9.4% | — |
| Nov 7, 2024 | AMC | -0.23 | -0.18 | +21.7% | 20.55 | +0.7% | +2.2% | +0.0% | -4.4% | -6.6% | -14.6% | — |
| Aug 8, 2024 | AMC | -0.21 | -0.25 | -19.0% | 18.15 | -4.1% | -8.3% | -8.3% | -5.0% | -5.8% | -1.7% | — |
| May 9, 2024 | AMC | -0.21 | -0.18 | +14.3% | 24.00 | +3.1% | +10.0% | +9.4% | +10.6% | +14.4% | +12.5% | — |
| Mar 4, 2024 | AMC | -0.20 | -0.22 | -10.0% | 13.50 | -1.0% | -1.8% | +1.1% | +6.1% | +1.0% | -7.6% | — |
| Nov 7, 2023 | AMC | -0.18 | -0.19 | -5.6% | 8.22 | -3.0% | -8.8% | -13.3% | -17.0% | -18.0% | -6.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | Wedbush | Maintains | Neutral → Neutral | — | $100.35 | $103.00 | +2.6% | -2.2% | -7.1% | -9.1% | -8.6% | -13.6% |
| Apr 21 | Citigroup | Maintains | Buy → Buy | — | $100.35 | $103.00 | +2.6% | -2.2% | -7.1% | -9.1% | -8.6% | -13.6% |
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $84.86 | $97.48 | +14.9% | +18.3% | +15.7% | +9.8% | +7.5% | +8.0% |
| Apr 20 | BTIG | Maintains | Buy → Buy | — | $84.86 | $97.48 | +14.9% | +18.3% | +15.7% | +9.8% | +7.5% | +8.0% |
| Mar 16 | Citigroup | Maintains | Buy → Buy | — | $73.25 | $75.38 | +2.9% | -1.4% | +2.5% | -0.1% | +2.2% | -1.4% |
| Feb 23 | B. Riley Securities | Maintains | Buy → Buy | — | $73.73 | $73.50 | -0.3% | -0.1% | -7.2% | -4.6% | -10.6% | -6.4% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.07 | $47.15 | +27.2% | +51.1% | +79.0% | +91.5% | +92.4% | +99.1% |
| Feb 10 | BTIG | Maintains | Buy → Buy | — | $37.07 | $47.15 | +27.2% | +51.1% | +79.0% | +91.5% | +92.4% | +99.1% |
| Jan 29 | BTIG | Maintains | Buy → Buy | — | $35.91 | $35.65 | -0.7% | -1.9% | +4.0% | +6.2% | +8.2% | +4.8% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.30 | $48.68 | -8.7% | -7.8% | -14.8% | -17.4% | -12.1% | -18.4% |
Recent Filings
8-K
Nektar Therapeutics -- 8-K Filing
Nektar Therapeutics completed a registered direct offering that became effective November 12, 2025, with supplemental prospectus documentation filed April 21, 2026, indicating capital raise activity for the biotech company.
Apr 23
8-K · 7.01
! Medium
Nektar Therapeutics -- 8-K 7.01: Regulation FD Disclosure
Nektar Therapeutics reported positive 52-week topline results from its REZOLVE-AA trial of rezpegaldesleukin for severe alopecia areata, potentially supporting future regulatory submissions for this novel treatment.
Apr 20
8-K · 7.01
! Medium
Nektar Therapeutics -- 8-K 7.01: Regulation FD Disclosure
Nektar Therapeutics reported approximately $741.7 million in cash and investments as of April 1, 2026, indicating a solid liquidity position to fund operations and potential investments.
Apr 20
8-K
Unknown — 8-K Filing
Nektar's Q4 2025 earnings announcement indicates the company remains focused on cash management during development stages, critical for biotechs burning capital while awaiting clinical trial outcomes and regulatory approvals.
Mar 12
8-K
Nektar Therapeutics -- 8-K Filing
Nektar Therapeutics will raise approximately $432 million in net proceeds from a public offering expected to close February 13, 2026, providing capital for operations and strategic initiatives.
Feb 13
8-K · 7.01
! Medium
Nektar Therapeutics -- 8-K 7.01: Regulation FD Disclosure
Nektar Therapeutics reported $229.1 million in cash and marketable securities as of January 31, 2026, indicating sufficient liquidity for near-term operations and development initiatives.
Feb 10
8-K · 7.01
! Medium
Nektar Therapeutics -- 8-K 7.01: Regulation FD Disclosure
Nektar Therapeutics reported positive 36-week interim results from its REZOLVE-AD trial of rezpegaldesleukin for moderate-to-severe atopic dermatitis, potentially advancing the candidate's regulatory pathway.
Feb 10
Data updated apr 26, 2026 3:12pm
· Source: massive.com